Valuation: CSL Limited

Market Cap 53.75B 46.4B 43.53B 39.65B 74.55B 5,139B 75.58B 510B 200B 2,575B 202B 197B 8,564B P/E 2027 *
26.6x
P/E 2028 * 14.8x
Enterprise Value 62.92B 54.32B 50.96B 46.41B 87.27B 6,016B 88.48B 597B 234B 3,014B 236B 231B 10,026B EV / Sales 2027 *
4.02x
EV / Sales 2028 * 3.78x
Free-Float
99.3%
Yield 2027 *
3.06%
Yield 2028 * 3.23%
1 day+17.25%
1 week+17.36%
Current month+28.25%
1 month+27.98%
3 months+61.11%
6 months+4.13%
Current year-8.59%
1 week 134.6
Extreme 134.6
159.25
1 month 113.75
Extreme 113.75
159.25
Current year 90
Extreme 90
184.62
1 year 90
Extreme 90
257
3 years 90
Extreme 90
313.55
5 years 90
Extreme 90
319.78
10 years 90
Extreme 90
342.75
Manager TitleAgeSince
Chief Executive Officer 63 2026-02-10
Director of Finance/CFO 52 2025-10-06
Chief Operating Officer - 2025-04-30
Director TitleAgeSince
Director/Board Member 72 2018-10-16
Director/Board Member 70 2011-02-01
Director/Board Member 71 2019-12-08
Date Insider Type Main position Quantity % Market Cap.
2/23/26 Free

Director

263 0.0001%
2/23/26 Free 512 0.0001%
2/19/26 Fiscal year

Director

183 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
+17.25%+17.36%-41.63%-41.46% 45.84B
+1.50%+2.47%+42.30%+0.53% 80.48B
-1.10%-2.42%-3.61%+28.98% 50.63B
+0.88%-3.93%+11.18%+169.94% 47.57B
+1.84%+4.31%+56.49%-18.56% 30.9B
-2.30%+2.95%+121.98%-38.64% 25.73B
+0.55%+2.64%+46.34%+94.05% 25.03B
+1.36%-0.67%-0.87%+195.57% 21.16B
+1.49%+5.39%+65.55%+127.59% 16.75B
+4.34%-1.32%+68.49%+187.59% 15.62B
Average +2.59%-0.50%+36.62%+70.56% 35.97B
Weighted average by Cap. +2.87%-0.83%+27.91%+49.16%

Financials

2027 *2028 *
Net sales 15.66B 13.52B 12.68B 11.55B 21.72B 1,497B 22.02B 149B 58.25B 750B 58.78B 57.51B 2,495B 16.15B 13.94B 13.08B 11.91B 22.4B 1,544B 22.71B 153B 60.09B 774B 60.64B 59.32B 2,573B
Net income 1.55B 1.34B 1.25B 1.14B 2.15B 148B 2.18B 14.71B 5.76B 74.2B 5.82B 5.69B 247B 3.09B 2.67B 2.5B 2.28B 4.29B 296B 4.35B 29.35B 11.5B 148B 11.6B 11.35B 493B
Net Debt 9.17B 7.92B 7.43B 6.77B 12.72B 877B 12.9B 87.09B 34.13B 439B 34.44B 33.69B 1,462B 7.34B 6.34B 5.95B 5.41B 10.18B 702B 10.32B 69.69B 27.31B 352B 27.56B 26.96B 1,170B
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,904
Date Price Change Volume
26-08-18 A$157.82 +17.25% 3,707,429
26-08-17 A$134.60 -1.39% 865,737
26-08-14 A$136.50 -0.74% 1,276,498
26-08-13 A$137.52 -0.66% 1,179,398
26-08-12 A$138.44 +0.08% 1,043,685
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
95.71USD
Average target price
97.57USD
Spread / Average Target
+1.95%

Quarterly revenue - Rate of surprise